Supplementary Materials for

Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

Running title: Diagnostic and prognostic performance of plasma p-tau181

Thomas K. Karikari1†, Andréa L. Benedet2†, Nicholas J. Ashton1,3,4,5†, Juan Lantero Rodriguez1, Anniina Snellman1,6, Marc Suárez-Calvet7,8,9,10, Paramita Saha Chaudhuri11, Firoza Lussier2, Hlin Kvartsberg1,13, Alexis Moscoso Rial1,3, Tharick A. Pascoal2,12, Ulf Andreasson1,13, Michael Schöll1,3, Pedro Rosa-Neto2,12, Kaj Blennow1,13‡, Henrik Zetterberg1,13,14,15‡\*

1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden; 2Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, H4H 1R3, Montreal, Canada; 3Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden; 4King’s College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK; 5NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK; 6Turku PET Centre, University of Turku, Kiinamyllynkatu 4-8, FI-20520 Turku, Finland; 7Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation. Barcelona, Spain; 8IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; 9Servei de Neurologia, Hospital del Mar, Barcelona, Spain; 10Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain; 11Department of Epidemiology and Biostatistics, McGill University, Montreal, Québec, Canada; 12Montreal Neurological Institute, H3A 2B4, Montreal, Canada; 13Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; 14Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; 15UK Dementia Research Institute at UCL, London, UK.

†Equal contribution as first authors

‡Equal contribution as senior authors

\*Corresponding author: Professor Henrik Zetterberg, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

Tel: +46 31-343 0142

Email: [henrik.zetterberg@clinchem.gu.se](mailto:henrik.zetterberg@clinchem.gu.se)

Supplementary Figures




Fig. S1. Longitudinal plasma p-tau181 data. Distribution of plasma p-tau181 at all time points. Baseline (month 0) was defined as the date of first plasma p-tau181 quantification.




Fig. S2. Concordance between biomarker cut-offs. Concordance plots indicate the proportion of subjects similarly classified using Aβ PET (a) or CSF p-tau181 (b) and plasma p-tau181 cut-offs.




Fig. S3. Cross-sectional associations by Aβ status. Linear regression analyses showing that plasma p-tau181 is differently associated with CSF and imaging biomarkers depending on Aβ PET status (a-h). Detailed description of the findings is reported in Supplementary Table S5.






Fig. S4. Cross-sectional associations by Aβ status. Linear regression analyses have shown that plasma p-tau181 differently associated with CSF and imaging biomarkers depending on the Aβ status (a-h). Detailed description of findings is reported in Supplementary Table S6.



**Fig. S5.** Plasma p-tau181 predicting cognitive decline and neurodegeneration. Linear mixed effect models indicate that high baseline plasma p-tau181 levels are associated with worse cognitive performance (a-c) and faster hippocampal atrophy (d) across diagnostic groups. An important observation evidenced in these plots is that MCI subjects that are positive for plasma p-tau181 reach biomarker follow-up levels observed at baseline of AD dementiagroups. The \* indicates the longitudinal trajectories that are significantly different from plasma p-tau181 negative CU (reference group).

Fig. S6. Plasma p-tau181 rate of change per group. Distribution of the average rate of change of plasma p-tau181 across diagnostic groups.

**Supplementary Tables**

Table S1. Analytical performance of plasma p-tau181 measurements across 3,758 ADNI samples.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Quality control sample** | ***n\**** | **Mean, pg/mL** | **Within-run CV%** | | **Between-run CV%** | |
| **SD** | **% CV** | **SD** | **% CV** |
| Low plasma sample | 47 | 6.0 | 0.7 | 11.6 | 0.8 | 12.7 |
| High plasma sample | 47 | 56.5 | 1.8 | 3.3 | 3.6 | 6.4 |

\*pooled data from quality control samples measured in duplicates at the start and the end of 47 separate analytical runs.

Table S2. Baseline participant characteristics according to clinical diagnosis.

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristica** | **CU (n=400)** | **MCI (n=558)** | **AD dementia (n=219)b** |
| Age at baseline, years | 74.8 (6.6) | 72.9 (7.9) \*,# | 75.9 (7.9) |
| Sex (female), No. (%) | 213 (53.3%)\* | 237 (42.5%)# | 89 (40.6%)# |
| *≥ 1 APOE* ε4, No. (%) | 113 (28.3%)\* | 255 (45.7%)\*,# | 147 (67.1%)# |
| Educational level, years | 16.5 (2.6) \* | 16.2 (2.7) # | 15.7 (2.6) # |
| **CSF biomarkers at baseline, mean(SD), ng/L** | | | |
| Aβ42 | 1050.4 (378.6)\* | 885.9 (341.3)\*,# | 650.6 (268.1)# |
| P-tau181 | 21.9 (10.7)\* | 26.8 (14.6)\*,# | 37.5 (16.0)# |
| Total-tau | 234.2 (97.8) \* | 276.8 (132.4)\*,# | 378.1 (150.4)# |
| **Neuroimaging measures at baseline, mean (SD)** | | | |
| AβPET | 1.0 (0.2) \* | 1.1 (0.2)\*,# | 1.2 (0.2) # |
| Hippocampal volume, mm3 | 7479.1 (827.8) \* | 7018.9 (1076.4) \*,# | 5825.4 (946.3) # |
| Whole brain, mm3 | 1050019.4 (65099.4) \* | 1051191.1 (65135.9) \* | 989678.1 (66609.9) # |
| Ventricular volume, mm3 | 35806.9 (16841.4) \* | 37805.4 (18992.1)\* | 50291.4 (20937.9) # |
| FDG-PET composite, | 1.3 (0.1) \* | 1.3 (0.1) \*,# | 1.1 (0.1) # |
| **Cognitive measures at baseline, mean (SD)** | | | |
| MMSE | 29.0 (1.3) \* | 28.0 (1.8) \*,# | 22.7 (3.0) # |
| CDR-SOB | 0.08 (0.3) \* | 1.5 (1.0) \*,# | 5.1 (2.3) # |
| ADAS-Cog | 5.6 (2.9) \* | 9.4 (4.4) \*,# | 21.3 (7.9) # |
| **Plasma biomarkers at baseline, pg/mL, mean (SD)** | | | |
| Plasma p-tau181 | 14.9 (9.0) \* | 18.3 (10.8) \*,# | 23.6 (8.8) # |
| Plasma NfL | 38.2 (23.0)\* | 40.7 (23.5) \* | 51.2 (22.6) # |

a Continuous variable are given as mean (SD)

b The AD group includes both Aβ+ and Aβ- participants

\*p<0.05 compared with the AD dementia group

#p<0.05 compared with the CU group

Continuous variables were compared with one-way ANOVA followed by Tukey’s post-hoc test. Categorical variables were compared with Chi-square test

Table S3. Number of participants with longitudinal biomarkers and cognitive measures.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Time-point,**  **month** | **Plasma** | **CSF** | **MRI** | **Aβ PET** | **FDG PET** | **Cognition** |
| **0** | 1177 | 288 | 969 | 1008 | 1022 | 1149 |
| **6** | 1 | 4 | 622 | 0 | 6 | 837 |
| **12** | 914 | 12 | 748 | 37 | 44 | 917 |
| **24** | 787 | 277 | 24 | 608 | 441 | 810 |
| **36** | 461 | 11 | 148 | 43 | 19 | 497 |
| **42** | 1 | 1 | 0 | 0 | 0 | 0 |
| **48** | 307 | 87 | 263 | 291 | 12 | 481 |
| **60** | 7 | 8 | 34 | 85 | 23 | 237 |
| **66** | 1 | 0 | 0 | 0 | 0 | 0 |
| **72** | 6 | 0 | 16 | 150 | 31 | 194 |
| **78** | 1 | 0 | 0 | 0 | 0 | 0 |
| **84** | 5 | 1 | 5 | 75 | 15 | 116 |
| **96** | 3 | 0 | 2 | 60 | 2 | 87 |
| **108** | 0 | 0 | 0 | 15 | 1 | 23 |
| **120** | 0 | 0 | 0 | 1 | 0 | 4 |

Table S4. Baseline associations between plasma p-tau181 and other biomarkers and cognitive measures according to clinical diagnosis.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All groups\*** | | **CU\*\*** | | **MCI\*\*** | | **AD\*\* b** | |
| **Baseline measure** | ***t*** | ***P*-value** | ***t*** | ***P*-value** | ***t*** | ***P*-value** | ***t*** | ***P*-value** |
| CSF Aβ42 | -8.271 | 6.11 x 10-16 | -3.125 | 0.00202 | -7.511 | 4 x 10-13 | -1.274 | 0.20482 |
| CSF total-tau | 7.596 | 7.64 x 10-14 | 2.462 | 0.0144 | 6.747 | 4.5 x 10-11 | 2.674 | 0.008446 |
| CSF p-tau181 | 8.782 | < 2 x 10-16 | 3.093 | 0.00217 | 7.709 | 7.78 x 10-14 | 2.982 | 0.00342 |
| Plasma NfL | 10.583 | < 2 x 10-16 | 5.678 | 2.63 x 10-8 | 7.795 | 3.21 x 10-14 | 4.143 | 5.34 x 10-5 |
| Aβ PET | 10.390 | < 2 x 10-16 | 3.462 | 0.000606 | 10.136 | < 2 x 10-16 | 0.731 | 0.46578 |
| Tau PET | 4.075 | 6.15 x 10-5 | 2.056 | 0.04172 | 3.710 | 0.00032 | NA | NA |
| Hippocampal volume | -4.477 | 8.48 x 10-6 | -2.249 | 0.0251 | -3.571 | 0.000391 | -0.782 | 0.43556 |
| Ventricular volume | 3.188 | 0.00148 | 1.821 | 0.0694 | 1.940 | 0.0529 | 1.623 | 0.106580 |
| Whole brain | -1.727 | 0.08452 | -0.352 | 0.725 | -1.395 | 0.164 | -1.039 | 0.30060 |
| FDG PET | -4.917 | 1.02 x 10-6 | 0.581 | 0.561274 | -5.111 | 4.51 x 10-7 | -1.095 | 0.275130 |
| MMSE | -2.601 | 0.00941 | -0.635 | 0.5258 | -3.000 | 0.002825 | -1.326 | 0.187 |
| CDR-SOB | 2.100 | 0.035915 | 0.441 | 0.6592 | 2.403 | 0.0166 | 2.188 | 0.02997 |
| ADAS-Cog | 5.040 | 5.43 x 10-7 | 2.772 | 0.005826 | 5.162 | 3.41 x 10-7 | 1.435 | 0.1530 |

\* Main effects of plasma p-tau181 on the biomarkers: the linear regression models were independently performed for each biomarker and were adjusted for age, sex and diagnosis.

**\*\*** Main effects of plasma p-tau181 on the biomarkers: the linear regression models were independently performed for each biomarker and within each diagnostic group. Models accounted for age and sex.

b The AD group includes only Aβ+ participants

Table S5. Baseline associations between plasma p-tau181 and other biomarkers and cognitive measures according to Aβ PET positivity.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All groups\*** | | **Aβ+ vs Aβ-\*\*** | |
| **Baseline measure** | ***t*** | ***P*-value** | ***t*** | ***P*-value** |
| CSF Aβ42 | -4.614 | 4.7 x 10-6 | 2.033 | 4.2 x 10-2 |
| CSF total-tau | 4.796 | 1.91 x 10-6 | 2.274 | 2.3 x 10-2 |
| CSF p-tau181 | 5.416 | 7.96 x 10-8 | 2.624 | 8.8 x 10-3 |
| Plasma NfL | 9.662 | < 2 x 10-16 | 3.524 | 4.4 x 10-4 |
| Aβ PET | 3.961 | 8 x 10-5 | 3.117 | 1.8 x 10-3 |
| Tau PET | 2.61 | 9.5 x 10-3 | 1.576 | 0.11 |
| Hippocampal volume | -5.360 | 1.06 x 10-7 | -2.446 | 0.014 |
| Ventricular volume | 4.907 | 1.09 x 10-6 | 1.807 | 0.071 |
| Whole brain | -3.589 | 3.9 x 10-4 | -1.567 | 0.11 |
| FDG PET | -5.528 | 4.16 x 10-8 | -3.732 | 2.0 x 10-4 |
| MMSE | -4.864 | 1.34 x 10-6 | -3.387 | 7.3 x 10-4 |
| CDR-SOB | 5.604 | 2.71 x 10-8 | 5.202 | 2.39 x 10-7 |
| ADAS-Cog | 5.936 | 4.03 x 10-9 | 4.915 | 1.04 x 10-6 |

\* Main effects of plasma p-tau181 on the biomarkers: the linear regression models were independently performed for each biomarker and were adjusted for age, sex and Aβ PET status.

**\*\*** Main effects of plasma p-tau181 on the biomarkers: linear regression models were performed testing the interaction between plasma p-tau181 and Aβ PET status. The outcomes reflect the difference between Aβ+ and Aβ- in the association between plasma p-tau181 and each of the biomarkers tested. Models were also adjusted for age and sex.

Table S6. Association of baseline plasma p-tau181 with downstream biomarkers of pathological progression

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **CU+\*** | | **MCI-\*** | | **MCI+\*** | |
| **Measure** | ***t*** | **p-value** | ***t*** | **p-value** | ***t*** | **p-value** |
| Plasma NfL | 0.57 | 0.56 | 0.29 | 0.76 | 1.08 | 0.26 |
| Hippocampal volume | -2.12 | 0.033 | -1.14 | 0.25 | -6.07 | 2.15 x 10-9 |
| FDG PET | 0.26 | 0.78 | 0.43 | 0.66 | -2.07 | 0.038 |
| MMSE | -2.23 | 0.025 | -2.87 | 4.2 x 10-3 | -10.63 | < 2 x 10-16 |
| CDR-SOB | 1.90 | 0.057 | 2.90 | 3.8 x 10-3 | 9.28 | < 2 x 10-16 |
| ADAS-Cog | 2.29 | 0.022 | 1.84 | 0.065 | 8.30 | 6.4 x 10-16 |

\*groups defined by plasma p-tau181 positivity. Data generated by comparing each group with the CU- group.